Ankyra Medical Journal (AnkMJ), formerly known as the Journal of Translational and Practical Medicine, regularly publishes international quality issues in the field of Medicine in the light of current information.

EndNote Style
Original Article
The relationship between sodium glucose co-transporter 2 inhibitors and diabetic ketosis/infection: single center retrospective experiences
Aims: Diabetes is a serious social problem in our country and around the world. Beyond hyperglycemia, it causes common and potentially life-threatening complications in all systems. For this reason, beyond the regulation of blood glucose, a holistic approach and combating complications are important in diabetes management. Sodium glucose co-transporter 2 inhibitors (SGLT2-i) are one of many antidiabetic drug families and stand out with their strong blood sugar regulation and cardiac and renal protective effects independent of blood sugar decrease. Despite its strong effectiveness, it is seen as risky in terms of diabetic ketosis and infection, which limits its use. We aimed to investigate the legitimacy of concerns by examining the relationship between SGLT-2 inhibitors and diabetic ketosis/infection.
Methods: Our study was designed single-center and retrospectively. 152 patients over the age of 18 who were treated as inpatients in our clinic with diabetic ketosis between January 2020 and June 2023 were included in the study. In these patients, ketosis and the severity of the infection clinic, if any, were examined through various parameters among Type 2 diabetic patients using SGLT-2 inhibitors, Type 2 diabetic patients not using SGLT-2 inhibitors, and Type 1 diabetes patients. These parameters were determined by the patient's blood and urine biochemistry tests at admission and discharge, the duration of ketosis treatment, the duration of intravenous antibiotic use, and the duration of hospitalization.
Results: Within the scope of the study, type 2 diabetic patients using SGLT-2 inhibitors were compared with type 2 diabetic patients not using SGLT-2 inhibitors and type 1 diabetic patients. In patients using SGLT-2 inhibitors, the leukocyte in urine, an indicator of urinary tract infection, was found to be significantly higher (p<0.002). When the blood biochemistry tests of the patients at the time of admission were compared in terms of ketosis severity, no significant difference was detected between the groups. No significant difference was detected in terms of ketosis treatment duration, intravenous antibiotic use duration, and hospitalization duration.
Conclusion: We believe that we have obtained data showing that ketoacidosis and infection complications associated with SGLT-2 inhibitors are manageable and controllable. Based on this, we recommend that further research be conducted on the side effects of SGLT-2 inhibitors, emphasizing their additional systemic benefits, and that the place of these agents in diabetic treatment should be discussed.

1. American Diabetes Association Professional Practice Committee.Classification and diagnosis of diabetes: standards of medical carein diabetes-2022. Diabetes Care. 2022;45(Supplement_1):17-38. doi:10.2337/dc22-S002
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care.1998;21(9):1414-1431.
3. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: global,regional and country-level diabetes prevalence estimates for 2021 andprojections for 2045. Diab Res Clin Pract. 2022;183:109119.
4. Satman I, Omer B, Tutuncu Y, et al. Twelve-year trends in the prevalenceand risk factors of diabetes and prediabetes in Turkish adults. Eur JEpidemiol. 2013;28(2):169-180.
5. Chadha C, Pittas AG, Lary CW, et al. Reproducibility of a prediabetesclassification in a contemporary population. Metabolism Open.2020;6:100031.
6. American Diabetes Association. Diagnosis and classification ofdiabetes mellitus. Diabetes Care. 2010;33(Supplement_1):S62-S69.
7. World Health Organization. Global report on diabetes. Geneva: WorldHealth Organization; 2016. World Health Organization. Global reporton diabetes Geneva World Health Organization, 2016.
8. Grant PJ. The effects of high-and medium-dose metformin therapy oncardiovascular risk factors in patients with type II diabetes. DiabetesCare. 1996;19(1):64-66.
9. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patientswith type 2 diabetes and acute coronary syndrome. N Engl J Med.2015;373(23):2247-2257.
10. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin andcardiovascular and renal events in type 2 diabetes. N Engl J Med.2017;377(7):644-657.
11. Donnan JR, Grandy CA, Chibrikov E, et al. Comparative safety ofthe sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematicreview and meta-analysis. BMJ Open. 2019;9(1):e022577.
12. Roden M, Merker L, Christiansen AV, et al. Safety, tolerability andeffects on cardiometabolic risk factors of empagliflozin monotherapyin drug-na&iuml;ve patients with type 2 diabetes: a double-blind extensionof a phase III randomized controlled trial. Cardiovasc Diabetol.2015;14(1):1-11.
13. Ferrannini E, Baldi S, Frascerra S,et al. Shift to fatty substrateutilization in response to sodium-glucose cotransporter 2 inhibition insubjects without diabetes and patients with type 2 diabetes. Diabetes.2016;65(5):1190-1195.
14. Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ,Pelleymounter MA. Weight loss induced by chronic dapagliflozintreatment is attenuated by compensatory hyperphagia in diet-inducedobese (DIO) rats. Obesity. 2012;20(8):1645-1652.
15. Yokono M, Takasu T, Hayashizaki Y, et al. SGLT2 selective inhibitoripragliflozin reduces body fat mass by increasing fatty acid oxidation inhigh-fat diet-induced obese rats. Eur J Pharmacol. 2014;727:66-74.
16. Uitrakul S, Aksonnam K, Srivichai P, Wicheannarat S, Incomenoy S.The incidence and risk factors of urinary tract infection in patientswith type 2 diabetes mellitus using SGLT2 inhibitors: a real-worldobservational study. Medicines. 2022;9(12):59.
17. Gadzhanova S, Pratt N, Roughead E. Use of SGLT2 inhibitors fordiabetes and risk of infection: analysis using general practice recordsfrom the NPS MedicineWise MedicineInsight program. Diab Res ClinPract. 2017;130:180-185.
18. Wilding J. SGLT2 inhibitors and urinary tract infections. Nat RevEndocrinol. 2019;15(12):687-688.
19. Jeon JY, Kim SK, Kim KS, et al. Clinical characteristics of diabeticketoacidosis in users and non-users of SGLT2 inhibitors. Diab Metabol.2019;45(5):453-457.
20. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose toketoacidosis. J Clin Endocrin Metab. 2015;100(8):2849-2852.
21. Liu J, Li L, Li S, et al. Sodium-glucose co-transporter-2 inhibitors andthe risk of diabetic ketoacidosis in patients with type 2 diabetes: asystematic review and meta-analysis of randomized controlled trials.Diab Obes Metab. 2020;22(9):1619-1627.
22. Hamblin PS, Wong R, Ekinci EI, et al. SGLT2 inhibitors increase therisk of diabetic ketoacidosis developing in the community and duringhospital admission. J Clin Endocrin Metab. 2019;104(8):3077-3087.
23. Yang H, Choi E, Park E, et al. Risk of genital and urinary tract infectionsassociated with SGLT-2 inhibitors as an add-on therapy to metforminin patients with type 2 diabetes mellitus: a retrospective cohort study inKorea. Pharmacol Res Perspect. 2022;10(1):e00910.
24. Almazrouei R, Afandi B, AlKindi F, Govender R, Al-Shamsi S. Clinicalcharacteristics and outcomes of diabetic ketoacidosis in patients withtype 2 diabetes using SGLT2 inhibitors. Clin Med Insights: EndocrinDiab. 2023;16:11795514231153717.
25. Papanastasiou L, Glycofridi S, Gravvanis C, et al. Diabetic ketoacidosisin patients treated with SGLT2 inhibitors: experience at a tertiaryhospital. Hormones. 2021;20(2):369-376.
26. Kim YG, Jeon JY, Han SJ, Kim DJ, Lee KW, Kim HJ. Sodium-glucoseco-transporter-2 inhibitors and the risk of ketoacidosis in patients withtype 2 diabetes mellitus: a nationwide population-based cohort study.Diab Obes Metab. 2018;20(8):1852-1858.
Volume 3, Issue 1, 2024
Page : 1-5